|
2008 Announcements 24 Dec 2008
Glypromate Trial Preliminary Results
10 Nov 2008
Glypromate Phase 3 Data Collection Completed
31 Oct 2008
Appendix 4C September 2008
30 Sep 2008
Change in Director's Interest Notice
30 Sep 2008
Change in Director's Interest Notice
30 Sep 2008
Appendix 3B (shares)
30 Sep 2008
Appendix 3B (options)
30 Sep 2008
SPP Results Sept 2008
29 Aug 2008
Appendix 4D June 2008
29 Aug 2008
Neuren Interim Report 2008
27 Aug 2008
Neuren signs out-licensing agreement
12 Aug 2008
Notice of Special Shareholders' Meeting
6 Aug 2008
Neuren raises minimum of $3 million
6 Aug 2008
Share Purchase Plan offer announced
6 Aug 2008
Appendix 3B 6 Aug 2008
31 Jul 2008
Appendix 4C June 2008
21 Jul 2008
Glypromate and NNZ-2566 included in Windhover Top 10 Neuroscience Projects
16 Jul 2008
Neuren Completes Glypromate Phase 3 Recruitment
30 Jun 2008
Neuren to get early results from Glypromate® trial
29 May 2008
Results of AGM
29 May 2008
CEO presentation to AGM
15 May 2008
Positive interim safety analysis for Glypromate®
30 Apr 2008
Appendix 4C - quarterly cash flows
29 Apr 2008
Quarterly Update to Shareholders April 2008
29 Apr 2008
Notice of Annual General Meeting/Proxy Form
31 Mar 2008
Annual Report 2007
18 Mar 2008
Co-CEOs remuneration packages
29 Feb 2008
Appendix 4E Preliminary Final Report
26 Feb 2008
Appendix 3B
11 Feb 2008
Change of Director`s Interest Notice
11 Feb 2008
Change of Director`s Interest Notice
11 Feb 2008
Rights issue raises $7.1m and notes convert
7 Feb 2008
Appendix 3B - shares issued on conversion of notes
7 Feb 2008
Appendix 3B - allotment of rights issue underwriter shares
5 Feb 2008
Notice under section 708A(5)(e)
1 Feb 2008
Appendix 3B - allotment of rights issue shares
31 Jan 2008
Neuren Appendix 4C December 2007
31 Jan 2008
Results of Rights Issue
22 Jan 2008
US Department of Defense Approves NNZ-2566 Funding
17 Jan 2008
Glypromate® trial recruits 100th patient
9 Jan 2008
Section 708AA Notice
|
